Lipid-Based Inhalable Micro- and Nanocarriers of Active Agents for Treating Non-Small-Cell Lung Cancer
Non-small-cell lung cancer (NSCLC) afflicts about 2 million people worldwide, with both genetic (familial) and environmental factors contributing to its development and spread. The inadequacy of currently available therapeutic techniques, such as surgery, chemotherapy, and radiation therapy, in addr...
Main Authors: | Sona Gandhi, Indrajit Roy |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/15/5/1457 |
Similar Items
-
Use of Microfluidics to Prepare Lipid-Based Nanocarriers
by: Alicia Vogelaar, et al.
Published: (2023-03-01) -
Nanocarriers for inhaled delivery of RNA therapeutics
by: Sebastian G. Huayamares, et al.
Published: (2024-01-01) -
Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers
by: Priya Muralidharan, et al.
Published: (2014-06-01) -
State-of-the-Art Review on Inhalable Lipid and Polymer Nanocarriers: Design and Development Perspectives
by: Gabriella Costabile, et al.
Published: (2024-03-01) -
Lipid-Based Nanocarrier System for the Effective Delivery of Nutraceuticals
by: Parthasarathi Subramanian
Published: (2021-09-01)